Shares Magazine
0.65p-0.03 (-3.70%)22 Jan 2025, 16:20
Jump to:
N4 Pharma PLC Fundamentals
| Company Name | N4 Pharma PLC | Last Updated | 2025-01-22 |
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
| Shares in Issue | 394.780 m | Market Cap | £2.57 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.01 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.0438 | Cash Equity Ratio | 0.9420 |
| Quick Ratio | 22.7328 | Current Ratio | 22.73 |
| Price To Book Value | 2.0530 | ROCE | 0 |
N4 Pharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
N4 Pharma PLC Company Financials
| Assets | 2023 | 2022 |
|---|---|---|
| Tangible Assets | 0 | 0 |
| Intangible Assets | £61,210.00 | 0 |
| Investments | 0 | 0 |
| Total Fixed Assets | £61,210.00 | 0 |
| Stocks | 0 | 0 |
| Debtors | £3,644.00 | £27,000.00 |
| Cash & Equivalents | £1.03 m | £1.92 m |
| Other Assets | 0 | 0 |
| Total Assets | £1.28 m | £2.17 m |
| Liabilities | 2023 | 2022 |
|---|---|---|
| Creditors within 1 year | £81,726.00 | £77,889.00 |
| Creditors after 1 year | 0 | 0 |
| Other Liabilities | 0 | 0 |
| Total Liabilities | £81,726.00 | £77,889.00 |
| Net assets | £1.19 m | £2.09 m |
| Equity | 2023 | 2022 |
|---|---|---|
| Called up share capital | £1.08 m | £935,121.00 |
| Share Premium | £14.87 m | £14.70 m |
| Profit / Loss | -£1.42 m | -£1.19 m |
| Other Equity | £1.13 m | £2.09 m |
| Preference & Minorities | £66,005.00 | 0 |
| Total Capital Employed | £1.19 m | £2.09 m |
| Ratios | 2023 | 2022 |
|---|---|---|
| Debt Ratio | 0 | 0 |
| Debt-to-Equity | 0 | 0 |
| Assets / Equity | 1.0438 | 1.0438 |
| Cash / Equity | 0.9420 | 0.9420 |
| EPS | -£0.01 | -£0.01 |
| Cash Flow | 2023 | 2022 |
|---|---|---|
| Cash from operating activities | -£1.21 m | -£828,263.00 |
| Cashflow before financing | -£893,198.00 | £135,505.00 |
| Increase in Cash | -£892,417.00 | £135,505.00 |
| Income | 2023 | 2022 |
|---|---|---|
| Turnover | £1,953.00 | 0 |
| Cost of sales | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Profit | -£1.42 m | -£1.19 m |
| Pre-Tax profit | -£1.42 m | -£1.19 m |
N4 Pharma PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | N4 Pharma PLC is the holding company for N4 UK. N4 UK is a specialist pharmaceutical company engaged in the development of nanoparticle silica delivery systems to improve the cellular delivery and potency of cancer treatments and vaccines. The company operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec. |
| Latest Interim Date | 24 Sep 2024 |
| Latest Fiscal Year End Date | 23 Apr 2024 |
N4 Pharma PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2017-05-03 | Professor Humayun Akhter Mughal | Non-Executive Director |
| 2018-04-25 | Mr. Gavin John Burnell | Executive Director,Chief Executive Officer |
| 2023-08-01 | Dr. John Chiplin | Non-Executive Director,Chairman |
| 2024-11-28 | Mr. Luke Sebastian Cairns | Executive Director |
| 2024-11-28 | Mr. Nigel Theobald | Executive Director,Chief Executive Officer |
| 2025-01-08 | Mr. David Templeton | Executive Director |
| 2022-02-24 | Mr. Paul Titley | Executive Director |
| 2024-11-28 | Dr. Christopher Jonathan Britten | Non-Executive Director,Chairman |
| 2024-11-28 | Dr. Michael G. Palfreyman | Non-Executive Director |
N4 Pharma PLC Contact Details
| Company Name | N4 Pharma PLC |
|---|---|
| Address | 60 Gracechurch Street, 6th Floor, London, EC3V 0HR |
| Telephone | +44 1332690061 |
| Website | https://www.n4pharma.com |
N4 Pharma PLC Advisors
| Solicitor | DWF LLP |
|---|---|
| Phone | 0113 261 6000 |
| Fax | 0870 094 0939 |
| Auditor | Saffery Champness |
|---|---|
| Phone | +44 2078414000 |
| Fax | +44 2078414100 |
| Financial PR Adviser | Alma PR |
|---|---|
| Phone | +44 2080044217 |
| Nominated Adviser | Stockdale Securities Ltd |
|---|---|
| Phone | +44 2076016100 |
| Stockbroker | Stockdale Securities Ltd |
|---|---|
| Phone | +44 2076016100 |
| Solicitor | Edwin Coe LLP |
|---|---|
| Phone | +44 2076914000 |
| Fax | +44 2076914111 |
| Auditor | Jeffreys Henry LLP |
|---|---|
| Phone | +44 2073092222 |
| Fax | +44 2073092309 |
| Bank | National Westminster Bank PLC |
|---|
| Stockbroker | Allenby Capital Limited |
|---|---|
| Phone | +44 2033285656 |
| Fax | +44 2033942970 |
| Financial Adviser | Allenby Capital Limited |
|---|---|
| Phone | +44 2033285656 |
| Fax | +44 2033942970 |
| Registrar | Neville Registrars Ltd |
|---|---|
| Phone | +44 1215851131 |
| Fax | +44 1215851132 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Intermediate Capital Group PLC | 2,258.00 | 6.61 |
| Alpha Group International PLC | 2,500.00 | 5.04 |
| Halma PLC | 2,951.00 | 4.09 |
| Entain PLC | 706.80 | 4.00 |
| Aviva PLC | 511.20 | 3.48 |
| Marshalls PLC | 243.50 | 2.96 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Hochschild Mining PLC | 193.40 | -15.55 |
| Trainline PLC | 358.60 | -8.52 |
| Easyjet PLC | 484.80 | -5.16 |
| Pennon Group PLC | 518.00 | -3.54 |
| Carnival PLC | 1,867.00 | -3.24 |
| Oxford Nanopore Technologies PLC | 150.40 | -2.97 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.